Company profile: Kedrion Biopharma
1.1 - Company Overview
Company description
- Provider of plasma-derived therapies and services, including RYPLAZIM (human plasminogen) for plasminogen deficiency type 1, Yimmugo (intravenous immunoglobulin G) for primary humoral deficiency in patients aged 2 years and older, plasma collection to produce plasma-derived medicinal products, and pharmacovigilance activities to detect, assess, understand, and prevent adverse effects.
Products and services
- Plasma Collection: Kedrion USA conducts donor-based collection of human plasma, supplying material used to produce plasma-derived medicinal products
- RYPLAZIM: A plasma-derived human plasminogen therapy used to treat plasminogen deficiency type 1 (PLGD-1), a rare chronic disease
- Yimmugo: An intravenous immunoglobulin G preparation produced to treat primary humoral deficiency in patients aged 2 years and older.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Kedrion Biopharma
Sairiyo Therapeutics
HQ: Canada
Website
- Description: Provider of biotechnology focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases, with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sairiyo Therapeutics company profile →
Attune Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology therapeutics, including ATN-249, an oral plasma kallikrein inhibitor for Hereditary Angioedema (HAE), and complement pathway inhibition approaches targeting the complement system to treat diseases such as Paroxysmal Nocturnal Hemoglobinuria (PNH).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Attune Pharmaceuticals company profile →
aTyr Pharma
HQ: United States
Website
- Description: Provider of biotherapeutics discovering and developing protein biologics, including efzofitimod, an immunomodulator targeting interstitial lung disease (pulmonary sarcoidosis and systemic sclerosis-related ILD); a tRNA synthetase biology platform; ATYR0101 targeting fibrosis via LTBP1; ongoing and completed efzofitimod clinical trials; and Pangu BioPharma developing bispecific antibodies for diseases like cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full aTyr Pharma company profile →
Vidara Therapeutics
HQ: United States
Website
- Description: Provider of specialty pharmaceutical offerings, creating value through accretive product acquisitions or license agreements, sound marketing and distribution, and life cycle management; incorporated in 2003 and based in Dublin, Ireland.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vidara Therapeutics company profile →
Retrotope
HQ: United States
Website
- Description: Provider of a drug platform to preserve and restore mitochondrial health in degenerative diseases, developing isotopically stabilized fatty acid therapeutics to control metabolic processes linked to oxidative stress. Products include RT001, a clinical-stage isotopically stabilized synthetic linoleic acid for INAD, FA, ALS, and PSP, and RT011, an isotopically stabilized synthetic DHA advancing towards clinical trials for dry AMD.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retrotope company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Kedrion Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Kedrion Biopharma
2.2 - Growth funds investing in similar companies to Kedrion Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Kedrion Biopharma
4.2 - Public trading comparable groups for Kedrion Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →